OM1 Expands Rheumatology Conditions With Specialized Data For Licensing And Advanced Analytics

BOSTON: OM1, a leading health outcomes, data and technology company today announced that its rheumatology registries, which track hundreds of thousands of patients longitudinally throughout the United States, are now available for direct licensing as well as studies and advanced analytics.
The registries include

Rheumatoid Arthritis
Systemic Lupus Erythematosus
Giant Cell Arteritis
Systemic Scleroderma
Juvenile Idiopathic Arthritis
Ankylosing Spondylitis
Hidradenitis Suppurativa

The OM1 registries are continually enrolling and updating and include patient reported outcomes as well as linkage to other data sources. These specialized clinical databases are used for streamlining research, understanding treatments and improving patient outcomes for life sciences companies and providers.

Understanding these conditions at a deeper level is critical to every stakeholder. We are proud to be advancing research and improving care through better, more complete and timely data, said Dr. Richard Gliklich, CEO of OM1. Enabling our customers to have direct access to research-grade data will help advance care even more rapidly.

The registry data is available for licensing and through OM1’s advanced data visualization and analytics tools. For more information, visit

Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *